Clinical Trial · NCT06200558

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Overview

Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN

Sponsor

Xiangya Hospital of Central South University

Contacts

Matteo Santoni (CONTACT)

sorgentoni.giulia@gmail.com

+39 07332573752

ClinicalTrials.gov

NCT06200558

Drug / Compound

PSMA-617

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

HRD POSITIVE STATUS
Histologically or radiologically confirmed diagnosis of metastatic disease andFor ARON-3S▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)For ARON-3Lu▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PCFor ARON-3GEN
Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
Cytological or Histologically confirmed diagnosis of PC

Exclusion

Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
HRD NEGATIVE STATUS
Patients without histologically confirmed diagnosis of PC
Patients without histologically or radiologically confirmed metastatic disease andFor ARON-3S▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria SectionFor ARON-3Lu▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PCFor ARON-3GEN